DAY 3 - Saturday, 24 October 2026
|
|
Topic:
|
Activity
|
Time
|
Learning Objectives
|
Category
|
Speaker
|
|
KEYNOTE TALKS (8am to 10.30am) 150 min
|
Evolving Trends in Skull Base Surgery
|
|
MODERATORS:
|
|
1
|
Advances in Microvascular Decompression Syndromes
|
Presentation
|
8am (30 min)
|
Describe recent advances in microvascular decompression for cranial nerve compression syndromes.
Identify refined indications and patient selection criteria for MVD.
Apply technical innovations to improve surgical safety and outcomes.
Evaluate clinical outcomes and complication profiles in contemporary MVD practice.
|
1
|
Christopher Honey (Canada)
|
|
2
|
Decision-making in Surgical Resection of Suprasellar Skull Base Lesions
|
Presentation
|
8.30am (30 min)
|
Identify key anatomical, radiological, and clinical factors influencing surgical decision-making for suprasellar skull base lesions.
Compare transcranial and endoscopic endonasal approaches based on lesion characteristics.
Evaluate risks to visual, vascular, and hypothalamic structures when planning resection.
Apply multidisciplinary and patient-specific considerations to optimize surgical outcomes.
|
1
|
Fahad AlKherayf (Canada)
|
|
3
|
Is Subtotal Resection Still Acceptable in Vestibular Schwannomas?
|
Presentation
|
9am (30 min)
|
Describe contemporary surgical goals and outcome measures in vestibular schwannoma management.
Compare outcomes of subtotal versus gross total resection, including tumor control and functional preservation.
Identify patient, tumor, and hearing-related factors influencing extent of resection.
Apply evidence-based decision-making to balance tumor control with facial and cochlear nerve preservation.
|
1
|
Jawad Yousaf (Qatar)
|
|
4
|
Modern Radiation Strategies in Skull Base Meningiomas
|
Presentation
|
9.30am (30 min)
|
Describe modern radiation modalities used in skull base meningiomas, including fractionated RT and radiosurgery.
Identify indications for radiation therapy across primary, residual, and recurrent disease.
Evaluate outcomes, risks, and neurocognitive considerations of contemporary radiation strategies.
Integrate radiation therapy into multimodal management of skull base meningiomas.
|
1
|
Raphael Bodensohn (Germany)
|
|
Panel Discussion
|
10am (30 min)
|
|
|
|
|
BREAK - 10.30am to 10.45am
|
|
PARALLEL SESSION 1 (10.45am to 12.30pm) 105 min
|
Advances in Spinal Neurosurgery-1
|
|
MODERATORS:
|
|
1
|
Cranio-Cervical Junction Instability: Evolving Diagnostic Criteria, Dynamic Imaging, and Surgical Indications
|
Presentation
|
10.45am (25 min)
|
Focus: evolving diagnostic criteria for instability, highlighting the role of dynamic imaging and how these advances refine surgical indications.
|
1
|
Dr. Ghaya
|
|
2
|
From Biomechanics to the Operating Room: Comparative Classification of Subaxial Spine Injuries and Its Influence on Surgical Strategy
|
Presentation
|
11.10am (20 min)
|
Focus: Biomechanical basic, compare AO Spine and SLIC/TLICS classification, surgical decision-making and operative strategy
|
1
|
Dr. Kazim
|
|
3
|
Innovative Fixation Techniques in Subaxial Cervical Spine Surgery
|
Presentation
|
11.30am (20 min)
|
Focus: emerging surgical fixation techniques, navigation-assisted, MIS, and patient-specific approaches that improve accuracy, stability, and clinical outcomes.
|
1
|
Dr. Raed Abu Jarir
|
|
4
|
Early Versus Delayed Surgery After Spinal Cord Injury: Does Timing Truly Matter?
|
Presentation
|
11.50am (20 min)
|
Focus: early or delayed surgical intervention, neurological and functional outcomes, current evidence and clinical practice.
|
1
|
Dr. Kazim
|
|
Panel Discussion
|
12.10pm (20 min)
|
|
|
|
Advances in Movement Disorder and Functional Neurousrgery
|
|
MODERATORS:
|
|
1
|
Overview of Hyperkinetic Movement Disorders and Advances in Therapeutics
|
Presentation
|
10.45am (15 min)
|
Describe the clinical spectrum and classification of hyperkinetic movement disorders.
Differentiate key phenomenology and underlying pathophysiology of common hyperkinetic syndromes.
Summarize recent advances in pharmacological, surgical, and neuromodulatory therapies.
Apply ndividualized, evidence-based treatment strategies to optimize patient outcomes.
|
1
|
Zakiyah Aldaajani (KSA)
|
|
2
|
Non-motor Manifestions of Parkinson - an update
|
|
11am (15 min)
|
Identify common and under-recognized non-motor manifestations of Parkinson’s disease.
Explain the pathophysiological mechanisms underlying non-motor symptoms.
Summarize updated pharmacologic and non-pharmacologic management strategies.
Integrate comprehensive non-motor assessment into routine Parkinson’s care.
|
|
Saeed Bohlega (KSA)
|
|
3
|
Recent Advances in the Treatment of Parkinson’s Disease
|
Presentation
|
11.15am (15 min)
|
Summarize recent advances in pharmacological, surgical, and device-based therapies for Parkinson’s disease.
Identify emerging treatments, including infusion therapies, neuromodulation, and disease-modifying strategies.
Evaluate evidence guiding treatment selection across different disease stages.
Apply individualized, multidisciplinary approaches to optimize motor and non-motor outcomes.
|
1
|
Shivam Mittal (UAE)
|
|
4
|
Patient Selection and Targeting Strategies in Deep Brain Stimulation
|
Presentation
|
11.30am (20 min)
|
Identify appropriate patient selection criteria for deep brain stimulation across movement and neuropsychiatric disorders.
Differentiate DBS targets based on disease phenotype, symptom profile, and therapeutic goals.
Apply imaging, neurophysiological, and clinical data to optimize targeting strategies.
Integrate multidisciplinary assessment to improve DBS outcomes and minimize complications.
|
1
|
Christopher Honey (Canada)
|
|
5
|
Intrathecal Baclofen Therapy: Indications, Patient Selection, and Outcomes
|
Presentation
|
11.50pm (20 min)
|
Describe the indications for intrathecal baclofen therapy in spasticity management.
Identify appropriate patient selection criteria and contraindications.
Outline perioperative considerations and device-related management.
Evaluate functional outcomes, complications, and long-term follow-up strategies.
|
1
|
Ghanem Al-sulaiti (Qatar)
|
|
Panel Discussion
|
12.10pm (20 min)
|
|
|
|
|
LUNCH BREAK - 12.30pm to 1.30pm
|
|
PARALLEL SESSION 2 (1.30pm to 3pm) 90 min
|
Advances in Spinal Neurosurgery-2
|
|
MODERATORS:
|
|
1
|
From Biomechanics to the Operating Room: Classification Systems and Surgical Strategy in Thoracolumbar Spine Trauma
Focus: biomechanical principles, comparing classification systems, to guide surgical indications, approach selection, and stabilization strategies
|
Presentation
|
1.30pm (20 min)
|
|
1
|
Dr. Ghaya
|
|
2
|
Innovative Surgical Techniques in Thoracolumbar Spine Trauma.
Focus: innovative surgical approaches, role of endoscopic, MIS and robotic techniques for fixation accuracy, reducing morbidity, and outcomes
|
Presentation
|
1.50pm (20 min)
|
|
1
|
Dr. Raed Abu Jarir
|
|
3
|
Precision Surgery in Spinal Tumors: Decision-Making Beyond the NOMS Framework Focus: precision surgical decision-making beyond the NOMS framework, with molecular biology, advanced imaging, stability, and patient-specific factors
|
Presentation
|
2.10pm (15 min)
|
|
1
|
Dr. Ghaya
|
|
4
|
Spinal Infections in the Modern Era: Evolving Strategies in Medical and Surgical Management
Focus: surgical decision-making in TB and brucellosis, indications for fixation, stability, deformity prevention, & integration of surgery with medical therapy
|
Presentation
|
2.30pm (15 min)
|
|
1
|
Dr. Raed Abu Jarir
|
|
Panel Discussion
|
2.50pm (20 min)
|
|
|
TBA
|
Neuroinflammation: Evolving Clinical Frontiers
|
|
1
|
MS, NMOSD, and MOGAD: Where Do They Overlap and Where Do They Diverge?
|
Presentation
|
1.30pm (20 min)
|
Differentiate the clinical, radiological, and immunological features of MS, NMOSD, and MOGAD.
Identify areas of overlap and key distinguishing characteristics among these disorders.
Interpret antibody testing and imaging findings to support accurate diagnosis.
Apply disease-specific management principles to optimize treatment decisions.
|
1
|
Shahd Hamid (Qatar)
|
|
2
|
The Next Era of Multiple Sclerosis Treatment
|
Presentation
|
1.50pm (20 min)
|
Describe emerging therapeutic strategies shaping the next era of multiple sclerosis treatment.
Identify advances in high-efficacy, immune reconstitution, and personalized therapies.
Evaluate evidence guiding early treatment, escalation, and de-escalation strategies.
Apply precision-based approaches to optimize long-term outcomes in MS care.
|
1
|
Eslam Shosha (KSA)
|
|
3
|
Hematopoietic Stem Cell Transplantation in CNS Inflammatory Disorders: Current Evidence and Future Directions
|
Presentation
|
2.10pm (15 min)
|
Describe the role of hematopoietic stem cell transplantation in CNS inflammatory disorders.
Identify indications and patient selection criteria based on current evidence.
Evaluate efficacy, risks, and long-term outcomes of HSCT in neuroinflammatory disease.
Discuss future directions and emerging data shaping HSCT use in neurology.
|
1
|
Basil Sharrack (UK)
|
|
4
|
Autoimmune Encephalitis: An Evolving Spectrum from Diagnosis to Targeted Treatment
|
Presentation
|
2.30pm (15 min)
|
Recognize the evolving clinical spectrum and red flags of autoimmune encephalitis.
Apply updated diagnostic algorithms, including antibody testing and imaging.
Differentiate autoimmune encephalitis from infectious and psychiatric mimics.
Integrate targeted immunotherapies into timely, individualized treatment plans.
|
1
|
Anu Jacob (UAE)
|
|
Panel Discussion
|
2.50pm (20 min)
|
|
|
|
|
BREAK 3pm to 3.15pm
|
|
PARALLEL SESSION 3 (3.15pm to 4.45pm)
|
|
|
ORAL FREE PAPERS (NEUROSURGERY)
|
|
MODERATORS:
|
|
1
|
|
Presentation and Q & A (7+3 min)
|
3.15pm
|
|
1
|
|
|
2
|
|
Presentation and Q & A (7+3 min)
|
3.25pm
|
|
1
|
|
|
3
|
|
Presentation and Q & A (7+3 min)
|
3.35pm
|
|
1
|
|
|
4
|
|
Presentation and Q & A (7+3 min)
|
3.45pm
|
|
1
|
|
|
5
|
|
Presentation and Q & A (7+3 min)
|
3.55pm
|
|
1
|
|
|
6
|
|
Presentation and Q & A (7+3 min)
|
4.05pm
|
|
1
|
|
|
7
|
|
Presentation and Q & A (7+3 min)
|
4.15pm
|
|
1
|
|
|
8
|
|
Presentation and Q & A (7+3 min)
|
4.25pm
|
|
1
|
|
|
9
|
|
Presentation and Q & A (7+3 min)
|
4.35pm
|
|
1
|
|
|
10
|
|
Presentation and Q & A (7+3 min)
|
4.45pm
|
|
1
|
|
ORAL FREE PAPERS (NEUROLOGY)
|
|
MODERATORS:
|
|
1
|
|
Presentation and Q & A (7+3)
|
3.15pm
|
|
1
|
|
|
2
|
|
Presentation and Q & A (7+3)
|
3.25pm
|
|
1
|
|
|
3
|
|
Presentation and Q & A (7+3)
|
3.35pm
|
|
1
|
|
|
4
|
|
Presentation and Q & A (7+3)
|
3.45pm
|
|
1
|
|
|
5
|
|
Presentation and Q & A (7+3)
|
3.55pm
|
|
1
|
|
|
6
|
|
Presentation and Q & A (7+3)
|
4.05pm
|
|
1
|
|
|
7
|
|
Presentation and Q & A (7+3)
|
4.15pm
|
|
1
|
|
|
8
|
|
Presentation and Q & A (7+3)
|
4.25pm
|
|
1
|
|
|
9
|
|
Presentation and Q & A (7+3)
|
4.35pm
|
|
1
|
|
|
10
|
|
Presentation and Q & A (7+3)
|
4.45pm
|
|
1
|
|
|
END OF DAY 3 SESSIONS
|
|
VOTE OF THANKS - 4.45pm
|
|
END OF CONFERENCE (5pm)
|
